Advertisement
Advertisement

More Related Content

Advertisement
Advertisement

Thyroid and heart disease

  1. THYROID AND CARDIOVASCULAR DISEASES Dr. I Tammi raju MD,DM. Dept of cardiology. ASRAM hospital.
  2. THYROID AND CVS Case 1 • A 25 year old female presented with SOB cl II-III . – Pulse 70/min, – BP- 100/60. – Echo-large pericardial effusion , no tamponade. – TSH- 33 mIU/mL. Recovered with thyroid correction Mild PE, BP-130/80.
  3. THYROID AND CVS Case 2 • 65 year old presented with palpitaions and NYHA class 4 breathlessness. – ECG- AF with FVR. – ECHO global hypokinesia , EF40% – TSH<0.01. • Stabilised and sinus rhythm was restored with antithyroid medications.
  4. THYROID AND CVS OVERVEIW • Introduction • Hemodynamics • Hypothyroid and heart • Hyperthyroid and heart • Subclinical hypothyroid and hyperthyroid • Amiodarone and heart.
  5. THYROID AND CVS INTRODUCTION • In ontogeny, the thyroid and heart anlage migrate together. • Thyroid gland and the heart share a close relationship that arises in embryology.
  6. THYROID AND CVS CARDIOVASCULAR HEMODYNAMICS
  7. THYROID AND CVS CARDIOVASCULAR HEMODYNAMICS • Thyroid hormone effects on the heart and peripheral vasculature include – decreased SVR and – increased resting heart rate, – Increase in left ventricular contractility, and – blood volume
  8. THYROID AND CVS • Vascular resistance • Thyroid harmone relaxes VSMCs, reduce peripheral vascular resistance. • Hypothyroidism decreases EDRF, thereby increasing peripheral vascular resistance. CARDIOVASCULAR HEMODYNAMICS
  9. CARDIAC CONTRACTION SERCA PHOSPHOLAMBAN SYSTEM SERCA Reuptake of calcium in early diastole Phosphorylation of Phospholamban relaxation of LV inhibits SERCA Contraction of LV inhibits T3 Cytosolic Calcium increase -- contraction decrease-- relaxation Ca++ Ca++
  10. THYROID AND CVS Diastolic function
  11. THYROID AND CVS • Herat rate • The pacemaker-related genes, are transcriptionally regulated by thyroid hormone. • Stimulation of -adrenergic receptors accelerates diastolic depolarization and increases heart rate.
  12. THYROID AND CVS • Basal metabolic rate • Thyroid hormone increases BMR in almost every tissue and organ system in the body. • This increased metabolic demands lead to changes in cardiac output, SVR, and blood pressure.
  13. THYROID AND CVS • Blood pressure • Hyperthyroidism: – Arterial stiffness is increased – Typically causes systolic blood pressure to rise – A widened pulse pressure • Hypothyroidism: – Endothelial dysfunction and impaired VSM relaxation lead to increased SVR. – lead to diastolic hypertension in 30% of patients.
  14. THYROID AND CVS • Cardiac output • Increased • In hyperthyroidism, cardiac output 50% to 300% higher than in normal individuals. • In hypothyroidism, decrease by 30% to 50%. • Restoration of normal cardiovascular hemodynamics can occur with treatment.
  15. THYROID AND CVS • Pulmonary Hypertension • Primarily in hyper thyroidism • The increase in cardiac output without the concomitant decline in pulmonary vascular resistance observed in the systemic circulation. • Some evidence exists that autoimmune disease may play a role in both hypothyroid- and hyperthyroid-linked cases of primary pulmonary hypertension.
  16. EFFECTS OF THYROID HORMONE ON CARDIOVASCULAR HEMODYNAMICS.
  17. CARDIOVASCULAR CHANGES WITH THYROID DISEASE
  18. THYROID AND CVS HYPOTHYROIDISM
  19. THYROID AND CVS HYPOTHYROIDISM • Major cardiovascular changes – decrease in cardiac output – decrease in cardiac contractility – reduction in heart rate – increase in peripheral vascular resistance. • Others – Hypercholesterolemia , – diastolic hypertension, – carotid intimal media thickness
  20. THYROID AND CVS • CLINICAL MANIFESTATIONS — • Exertional dyspnea and exercise intolerance -due to skeletal muscle dysfunction. • Cardiac dysfunction with poor contractility, dilatation • Edema, often nonpitting
  21. THYROID AND CVS Rhythm • Bradycardia • Low QRS voltage • Widespread T-wave inversions (usually without ST deviation) • QT prolongation-rarely Torsedes • First degree AV block • Interventricular conduction delay
  22. THYROID AND CVS • Mechanism • Myxoedematous deposits within the myocardium. • Decreased activity of the sympathetic nervous system. • Effects on the myocardium of reduced levels of thyroxine (i.e. reduced inotropy/chronotropy)
  23. THYROID AND CVS Bradycardia (30 bpm) with Low QRS voltages (esp. in the limb leads). and widespread T-wave inversions. MYXOEDEMA
  24. THYROID AND CVS AFTER THERAPY Rate- 70 bpm Disappearance of T-wave inversions.
  25. THYROID AND CVS PERICARDIAL EFFUSION •Pericardial effusions, in approximately 25% of patients and may be quite large. •Increased systemic capillary permeability and disturbances in electrolyte metabolism. • characterized by a high protein and cholesterol content.
  26. THYROID AND CVS • Lipid abnormalities and others: – Marked increase LDL and apo B- • cholesterol 7-hydroxylase is negatively regulated by T3(decreased cholesterol catabolism) – High Homocysteine – High Creatine kinase — The isoenzyme distribution is almost completely MM,indicating skeletal muscle, not myocardial.
  27. THYROID AND CVS • Accelerated coronary artery disease . – Hypercholesterolemia – Diastolic hypertension, and – Elevated homocysteine levels – Elevated C-reactive protein and – Endothelial dysfunction • Patients with angina pectoris probably have less symptoms as they are less active and peripheral oxygen demands decrease.
  28. TREATMENT • In older patients or those with a history of angina, begin therapy with a low dose of T4, as an example 12.5 or 25 mcg daily, because of the possibility of inducing an arrhythmia or an exacerbation of angina. • If revascularization is indicated better to start T4 after the procedure.
  29. THYROID AND CVS HYPERTHYROIDISM
  30. THYROID AND CVS HYPERTHYROIDISM • Increases in – heart rate – cardiac contractility, – systolic and mean pulmonary artery pressure, – cardiac output, diastolic relaxation, and – myocardial oxygen consumption • Reductions in – systemic vascular resistance and – diastolic pressure
  31. THYROID AND CVS • Tachycardia, at rest, during sleep, and exaggerated during exercise. • Palpitations – tachy/forceful cardiac contractility • Hyperdynamic precordium. • Systolic hypertension with widened pulse pressure • Exertional dyspnea, which is due to respiratory and skeletal muscle weakness Clinical features
  32. THYROID AND CVS • Means–Lerman scratch • Uncommon heart murmur which occurs in patients with hyperthyroidism. • It is a mid-systolic scratching sound best heard over the second left intercostal space at the end of expiration. • Results from the rubbing of the pericardium against the pleura in the context of hyperdynamic circulation and tachycardia, • Mimic the sound of a pericardial rub.
  33. THYROID AND CVS ANGINA PECTORIS • Increase in cardiac oxygen consumption, due either to a – direct effect of triiodothyronine (T3) on cardiac muscle or to an – increase in peripheral oxygen demand. • Prinzmetal angina – In the young patient with normal coronary anatomy, this may be due to coronary vasospasm .
  34. THYROID AND CVS RHYTHM • Atrial tissue is very sensitive to the effects of thyroid hormone . • More – APCs, – non-sustained SVT, – VPCs, • Reduced heart rate variability
  35. THYROID AND CVS RHYTHM ATRIAL FIBRILLATION • 2% and 20%. • Associated with – Male sex, – increasing age , >60yrs. – coronary heart disease. – heart failure. – valvular heart disease . • subclinical hyperthyroidism -- same relative risk
  36. THYROID AND CVS ATRIAL FIBRILLATION
  37. THYROID AND CVS • Treatment of AF- – BB- beta1-selective or nonselective agent to control the ventricular response – Digoxin- better avoid decreased sensitivity to this drug – CCB- may lead to hypotension. • Anticoagulation is controversial. – Increased vitamin K metabolism leading to an increase in sensitivity to warfarin anticoagulation. – Advancing age is the main risk factor – Asprin is effective safe alternative.
  38. THYROID AND CVS HEART FAILURE
  39. THYROID AND CVS HEART FAILURE • High output failure- not used these days • Factors responsible – Exaggerated sinus tachycardia or – atrial fibrillation (rate-related) – Mitral valve prolapse (MVP)– MR • Increased prevalence in Graves’ and Hashimoto’s diseases . • Treated with BB and I 131.
  40. THYROID AND CVS PULMONARY HYPERTENSION • PH has been reported with increasing frequency in patients with overt hyperthyroidism. • Pulmonary artery pressures average twice normal values (10 mmHg) and may be as high as 30 to 50 mmHg. • These changes reverse with treatment of the hyperthyroidism .
  41. THYROID AND CVS MOYAMOYA DISEASE • Characterized by anatomic occlusion of the terminal portions of internal carotid arteries. • In these patients, treatment of the hyperthyroidism can prevent further cerebral ischemic symptoms. • This reinforces the importance of routine thyroid function tests (to include TSH) in patients who present with cardiac and cerebral vascular ischemic symptoms » Im SH, Oh CW, Kwon OK, Kim JE, Han DH. Moyamoya disease associated with Graves disease: , J Neurosurg. 2005;102:1013–1017
  42. THYROID AND CVS SUBCLINICAL HYPO & HYPER THYROIDISM
  43. THYROID AND CVS SUBCLINICAL HYPOTHYROIDISM • On TSH screening, the magnitude of subclinical thyroid disease may exceed that of overt disease by threefold to fourfold.
  44. THYROID AND CVS • Subclinical hypothyroidism alters – lipid metabolism, – atherosclerosis, – cardiac contractility, and – systemic vascular resistance (endothelium- dependent vasodilation). • Presence of antithyroid antibodies increases risk
  45. THYROID AND CVS • Patients with subclinical hypothyroidism have – prolonged isovolumic relaxation times, – systolic contractile function does not change . • Replacement with T4 at a mean dose of 68 μg/day (range, 50 to 100 μg/day) – restored isovolumic relaxation times to normal, – systemic vascular resistance declined and – systolic function improved significantly
  46. THYROID AND CVS • Study from the U.K. General Practitioners data base showed that treatment of TSH levels between 5 and 10 mIU/mL lowered the incidence of ischemic heart disease events and cardiovascular mortality in patients younger than 70 years.
  47. THYROID AND CVS SUBCLINICAL HYPERTHYROIDISM • Serum TSH level is low (<0.1 mIU/mL) and T4 and T3 levels are normal. • The prevalence of atrial fibrillation after 10 years was 28% Vs 11% with a relative risk of 3.1.
  48. THYROID AND CVS • Therapy can be individualized with regard to three specific groups. • The first group – excessive thyroid medication, needs reduction of dose. • The second group – Previous diagnosis of thyroid cancer who are receiving T4 to suppress TSH. – younger patients -- beta blockers can useful – In older patients, lowering the T4 dosage .
  49. THYROID AND CVS • The third group – Endogenous thyroid gland overactivity, including Graves disease or nodular goiter. – Older patients are at risk for AF – Methimazole 5 to 10 mg/day – Consideration should be given to the use of radioiodine for definitive therapy.
  50. THYROID AND CVS AMIODARONE AND THYROID FUNCTION
  51. THYROID AND CVS AMIODARONE AND THYROID FUNCTION • Thyroid dysfunction in 60% of pts treated . • Why – Amiodarone is an iodine-rich (30% iodine content by weight) – structural similarity to levothyroxine • Either – hypothyroidism (5% to 25% of treated patients) or – hyperthyroidism (2% to 10% of treated patients) in iodine-deficient areas.
  52. THYROID AND CVS AMIODARONE INDUCED HYPOTHYROIDISM(AIH) 100mg amiodarone 3mg iodine. Risk factors Preexistent thyroid disease. Hashimoto’s thyroiditis. Inhibition of 5 -deiodinase activity Inhibits T4 to T3 The average iodine content in diet is about 0.3 mg/day. Directly inhibit thyroid gland function
  53. THYROID AND CVS TREATMENT of AIH • Levothyroxine. • Monitoring TFT regularly.
  54. THYROID AND CVS AMIODARONE-INDUCED THYROTOXICOSIS (AIT) • Less common but perhaps more challenging. • 2% to 10% and vary directly with duration . • Onset was often sudden, during chronic treatment, or up to 1 year after stopping therapy.
  55. THYROID AND CVS • 2 forms of AIT exist. • Type 1 hyperthyroidism – with preexistent thyroid disease and goiter. – more often in regions where iodine intake is low. • Type 2 hyperthyroidism is caused by an – inflammatory process that causes increased release of thyroid hormones from a previously normal thyroid gland. • Sometimes Difficult to distinguish between them.
  56. THYROID AND CVS • TREATMENT OF TYPE I AIT: • Thionamides — may be slow response and large doses may be required. • Surgery — Patients who are refractory to antithyroid drug therapy should be treated by thyroidectomy. • Radioiodine ablation - is usually not an option due to low radioiodine uptake in these patients as they are iodine excess in body.
  57. THYROID AND CVS • Caution: • Amiodarone appears to ameliorate hyperthyroidism by blocking T4 to T3 conversion, beta-adrenergic receptors, and possibly T3 receptors. • Amiodarone should not be discontinued until hyperthyroid symptoms are well controlled since worsening of hyperthyroid symptoms due to increased T3 levels.
  58. THYROID AND CVS • TREATMENT OF TYPE II AIT • Glucocorticoids — • Patients with type II hyperthyroidism respond well to moderately large doses of corticosteroids (eg, prednisone 40 to 60 mg/day) even if the amiodarone is continued.
  59. THYROID AND CVS Whether to continue amiodarone…… • Since the t1/2 is about 100 days, there is no immediate benefit on stopping amiodarone. • Continue for life-threatening ventricular arrhythmias. • If not for life-threatening ventricular arrhythmias discontinue if alternative can be used.
  60. THYROID AND CVS • Treatment if mechanism unknown /“Mixed”form: • combinationof prednisone (40 mg/day) and m ethimazole (40 mg/day) is prudent initial therapy. – A rapid response suggests type II hyperthyroidism; the methimazole can then be tapered or stopped and, – A poor response initially argues for type I hyperthyroidism. If so, steroids can be tapered.
  61. THYROID AND CVS
  62. THYROID AND CVS Changes in Thyroid Hormone Metabolism That Accompany Cardiac Disease Decrease in serum T3.
  63. THYROID AND CVS • Low serum T3 level strongly predicts all-cause and cardiovascular mortality. • In ACS Serum T3 levels fall by about 20% and reach a nadir after approximately 96 hours. • Up to 30% of patients with heart failure have a low serum T3 level. • In view of the deleterious effects of hypothyroidism on the myocardium, T3 replacement may provide benefit.
  64. THYROID AND CVS When to check Thyroid Function Testing • Unexplained AF • Unexplained CHF • Pericardial effusion • Diastolic hypertension • On amiodarone every 3 months. • Hyperlipidemia • Critically ill patients.
  65. THYROID AND CVS When the Thyroid Speaks…the Heart Listens” MA Sussman.,Circ. Res 2001 THANKYOU
Advertisement